644 completed, 239 terminated, 166 recruiting, 121 unknown. 1358 Phase 1, 499 Phase 2.
Follow Blood Protein Disorders: new trials by email Literature Review of Blood Protein Disorders trials Research Report on Blood Protein Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Engineered Dendritic Cell Vaccines for Multiple Myeloma DC vaccines - Multiple Myeloma or Plasmacytoma | Phase 1 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 10 | 2027-06-30 | 2026-08-27 |
| ²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma Allogeneic Hematopoietic Stem Cell Transplantation, Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10, Cyclophosphamide - Multiple Myeloma, Recurrent Multiple Myeloma | Phase 1 | Withdrawn | Fred Hutchinson Cancer Center | 2027-06-01 | 2026-09-11 | |
| Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 162 | 2027-04-12 | 2026-10-16 |
| Microbiome Intervention for CAR-T Optimization and Response (MICRO-CART) Live Biotherapeutic Product (LBP), Placebo - Lymphoma, B-Cell, Multiple Myeloma | Phase 1 | Not yet recruiting | University of Chicago | 32 | 2027-02-23 | 2026-10-22 |
| Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma CAR-T cells - Multiple Myeloma, Plasmacytoma | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 20 | 2026-12-31 | 2026-08-27 |
| Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma CAR T cells - Multiple Myeloma | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 20 | 2026-12-31 | 2026-10-30 |
| Etenta-Isa-VRd in Newly Diagnosed High-Risk Multiple Myeloma Etentamig, Isatuximab, Bortezomib + Lenalidomide + Dexamethasone - Myeloma Multiple, Myeloma | Phase 1 / Phase 2 | Not yet recruiting | Universitätsklinikum Hamburg-Eppendorf | 220 | 2026-12-01 | 2026-05-20 |
| Study of Belantamab Mafodotin, Cevostamab, Pomalidomide for RRMM Patients (MAPLE) Belamaf, Cevostamab, Pomalidomide - Relapsed Refractory Multiple Myeloma (RRMM) | Phase 1 | Not yet recruiting | Canadian Myeloma Research Group | 108 | 2026-12-01 | 2026-09-21 |
| A Multicenter Study of Belantamab Mafodotin and Mezigdomide in Patients With Relapsed Multiple Myeloma CAR-T cells, BCMA bispecific - Myeloma Multiple | Phase 1 / Phase 2 | Not yet recruiting | Centre Hospitalier Universitaire de Saint Etienne | 44 | 2026-12-01 | 2026-10-09 |
| Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma Mirdametinib, Sirolimus - Multiple Myeloma, Relapsed and/or Refractory Multiple Myeloma (RRMM) | Phase 1 / Phase 2 | Suspended | National Cancer Institute (NCI) | 54 | 2026-11-04 | 2026-10-30 |
| Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies aldesleukin, cyclophosphamide, fludarabine phosphate - Malignancy, Hematologic, Neoplasms, Hematologic | Phase 1 | Recruiting | National Cancer Institute (NCI) | 86 | 2026-11-04 | 2026-10-30 |
| Low-Dose TBI Plus CAR T-Cell Therapy for Relapsed/Refractory DLBCL and Multiple Myeloma Lymphodepleting chemotherapy: Cyclophosphamide, Lymphodepleting chemotherapy: Bendamustine, Lymphodepleting chemotherapy: Fludarabine - Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed or Refractory Multiple Myeloma (MM) | Phase 1 | Recruiting | Weill Medical College of Cornell University | 32 | 2026-11-01 | 2026-10-26 |
| Phase 1a/b Study of GPRC5D CART Therapy in Relapsed/Refractory Multiple Myeloma and Light-chain Amyloidosis GPRC5D CART - Relapsed/Refractory Multiple Myeloma (RRMM), Light-Chain Amyloidosis | Phase 1 | Not yet recruiting | Hadassah Medical Organization | 160 | 2026-11-01 | 2026-10-20 |
| A Study of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Multiple Myeloma and Moderate Hepatic Impairment Belantamab mafodotin, Bortezomib, Dexamethasone - Multiple Myeloma | Phase 1 | Not yet recruiting | GlaxoSmithKline | 20 | 2026-10-23 | 2026-05-27 |
| Base-Edited Hematopoietic Stem/Progenitor Cell Gene Therapy for Treatment of CXCR4-WHIM Busulfan, Palifermin, Plerixafor - WHIM, Warts | Phase 1 / Phase 2 | Enrolling by invitation | National Institute of Allergy and Infectious Diseases (NIAID) | 10 | 2026-10-21 | 2026-10-27 |
| A Study to Evaluate the Subcutaneous Belantamab (BCMAb) Formulation Versus Intravenous Belantamab in Participants With Multiple Myeloma While Treated With Standard of Care Belantamab SC, Belantamab IV, Recombinant Human Hyaluronidase PH20 (rHuPH20) - Multiple Myeloma | Phase 1 | Not yet recruiting | GlaxoSmithKline | 22 | 2026-10-16 | 2026-08-03 |
| A Phase I Clinical Study on the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Characteristics of GLR1075 Injection in Healthy Trial Participants and Cirrhotic Trial Participants With Ascites and Hypoalbuminemia placebo GLR1075 Vehicle, Human Serum Albumin(HSA), GLR1075 Injection - Hypoalbuminemia in Cirrhotic Ascites | Phase 1 | Not yet recruiting | Gan & Lee Pharmaceuticals. | 106 | 2026-10-07 | 2026-10-01 |
| A Phase I, Open-label, Multicenter Study to Evaluate the Safety and Tolerability of BP2202 in Patients With Relapsed/Refractory Multiple Myeloma BP2202 - Relapsed/Refractory Multiple Myeloma (RRMM) | Phase 1 | Not yet recruiting | BrightPath Biotherapeutics Co., Ltd. | 18 | 2026-10-01 | 2026-08-21 |
| A Phase 1 Study of UB-VV500 With Rapamycin in Relapsed/Refractory Multiple Myeloma UB-VV500, Rapamycin (sirolimus) - Multiple Myeloma in Relapse, Multiple Myeloma (MM) | Phase 1 | Not yet recruiting | Umoja Biopharma | 100 | 2026-10-01 | 2026-08-17 |
| FT836 CAR T-cell Therapy in Combination With Daratumumab in Patients With Relapsed and/or Refractory Multiple Myeloma FT836 CAR T cells (1 x 10^8 cells per dose), FT836 CAR T cells (3 x 108 cells per dose), FT836 CAR T cells (up to 9 x 108 cells per dose) - Relapse Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 | Not yet recruiting | Medical College of Wisconsin | 12 | 2026-10-01 | 2026-08-10 |
Showing 20 of 1358. Sign in to see all of them.
Multiple Myeloma (1190) · Lymphoma, Non-Hodgkin (244) · Leukemia, Lymphocytic, Chronic, B-Cell (237) · Lymphoma, Follicular (213) · Lymphoma, Mantle-Cell (212) · Waldenstrom Macroglobulinemia (211) · Lymphoma, B-Cell, Marginal Zone (200) · Lymphoma, Large B-Cell, Diffuse (195) · Lymphoma (184) · Recurrence (182) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (173) · Neoplasms, Plasma Cell (169) · Hodgkin Disease (164) · Burkitt Lymphoma (149) · Leukemia, Myeloid, Acute (140)
Hemic and Lymphatic Diseases (1358) · Immune System Diseases (1348) · Cardiovascular Diseases (1340) · Immunoproliferative Disorders (1340) · Vascular Diseases (1337) · Hemorrhagic Disorders (1336) · Neoplasms by Histologic Type (1336) · Hemostatic Disorders (1335) · Hematologic Diseases (1333) · Paraproteinemias (1330) · Lymphoproliferative Disorders (1327) · Neoplasms (1273) · Neoplasms, Plasma Cell (1174) · Lymphatic Diseases (450)
Dexamethasone (265) · Lenalidomide (142) · Bortezomib (133) · Cyclophosphamide (114) · Calcium Dobesilate (97) · pomalidomide (82) · carfilzomib (72) · Melphalan (68) · daratumumab (61) · fludarabine (57) · fludarabine phosphate (51) · Rituximab (47) · Filgrastim (39) · Peripheral Blood Stem Cell Transplantation (35) · dexamethasone acetate (34)
National Cancer Institute (NCI) (73) · Mayo Clinic (37) · Celgene (34) · M.D. Anderson Cancer Center (26) · Memorial Sloan Kettering Cancer Center (26) · GlaxoSmithKline (23) · AbbVie (21) · Fred Hutchinson Cancer Center (21) · Amgen (18) · City of Hope Medical Center (18) · Janssen Research & Development, LLC (17) · Novartis Pharmaceuticals (16) · Millennium Pharmaceuticals, Inc. (15) · Washington University School of Medicine (14) · Masonic Cancer Center, University of Minnesota (13)
United States (955) · China (160) · Spain (115) · France (103) · Australia (98) · Canada (85) · Germany (76) · Italy (70) · United Kingdom (63) · Japan (58) · South Korea (51) · Israel (41) · Greece (31) · Netherlands (30) · Belgium (25)
Paul Richardson, MD (6) · James R Berenson, MD (5)
PMID 34398557, PMID 36100310, PMID 37022569, PMID 28803351, PMID 32499241, PMID 34515338, PMID 37192741, PMID 19238148, PMID 26370838, PMID 26943915, PMID 27412889, PMID 31215818, PMID 31527168, PMID 33980831, PMID 36375120, PMID 37270762, PMID 37658205, PMID 40000533, PMID 40826257, PMID 41100731, PMID 41118600, PMID 42287565, PMID 10552943, PMID 10564685, PMID 10613347, PMID 10764422, PMID 12171484, PMID 12473574, PMID 12752100, PMID 14767498, PMID 15241836, PMID 15466934, PMID 15570084, PMID 15902208, PMID 15958804, PMID 16061911, PMID 17020988, PMID 17312328, PMID 17975015, PMID 18032762, PMID 18032763, PMID 18202410, PMID 18297527, PMID 18327587, PMID 18418404, PMID 18463792, PMID 18470481, PMID 18768528, PMID 18974373, PMID 19179301
2023 (36), P30CA015083 (17), 2019 (15), 2018 (10), 2016 (9), U01CA076576 (9), P30CA006973 (8), P30CA016058 (8), 2015 (7), 2017 (7), P30CA015704 (7), P30CA022453 (7), P30CA033572 (7), U01CA069912 (7), 2025 (6)